First Time Loading...

Immunome Inc
NASDAQ:IMNM

Watchlist Manager
Immunome Inc Logo
Immunome Inc
NASDAQ:IMNM
Watchlist
Price: 14.54 USD -1.02% Market Closed
Updated: May 2, 2024

Intrinsic Value

IMNM's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. [ Read More ]

The intrinsic value of one IMNM stock under the Base Case scenario is 1.3 USD. Compared to the current market price of 14.54 USD, Immunome Inc is Overvalued by 91%.

Key Points:
IMNM Intrinsic Value
Base Case
1.3 USD
Overvaluation 91%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Immunome Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IMNM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Immunome Inc

Provide an overview of the primary business activities
of Immunome Inc.

What unique competitive advantages
does Immunome Inc hold over its rivals?

What risks and challenges
does Immunome Inc face in the near future?

Has there been any significant insider trading activity
in Immunome Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Immunome Inc.

Provide P/S
for Immunome Inc.

Provide P/E
for Immunome Inc.

Provide P/OCF
for Immunome Inc.

Provide P/FCFE
for Immunome Inc.

Provide P/B
for Immunome Inc.

Provide EV/S
for Immunome Inc.

Provide EV/GP
for Immunome Inc.

Provide EV/EBITDA
for Immunome Inc.

Provide EV/EBIT
for Immunome Inc.

Provide EV/OCF
for Immunome Inc.

Provide EV/FCFF
for Immunome Inc.

Provide EV/IC
for Immunome Inc.

Show me price targets
for Immunome Inc made by professional analysts.

What are the Revenue projections
for Immunome Inc?

How accurate were the past Revenue estimates
for Immunome Inc?

What are the Net Income projections
for Immunome Inc?

How accurate were the past Net Income estimates
for Immunome Inc?

What are the EPS projections
for Immunome Inc?

How accurate were the past EPS estimates
for Immunome Inc?

What are the EBIT projections
for Immunome Inc?

How accurate were the past EBIT estimates
for Immunome Inc?

Compare the revenue forecasts
for Immunome Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Immunome Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Immunome Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Immunome Inc compared to its peers.

Compare the P/E ratios
of Immunome Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Immunome Inc with its peers.

Analyze the financial leverage
of Immunome Inc compared to its main competitors.

Show all profitability ratios
for Immunome Inc.

Provide ROE
for Immunome Inc.

Provide ROA
for Immunome Inc.

Provide ROIC
for Immunome Inc.

Provide ROCE
for Immunome Inc.

Provide Gross Margin
for Immunome Inc.

Provide Operating Margin
for Immunome Inc.

Provide Net Margin
for Immunome Inc.

Provide FCF Margin
for Immunome Inc.

Show all solvency ratios
for Immunome Inc.

Provide D/E Ratio
for Immunome Inc.

Provide D/A Ratio
for Immunome Inc.

Provide Interest Coverage Ratio
for Immunome Inc.

Provide Altman Z-Score Ratio
for Immunome Inc.

Provide Quick Ratio
for Immunome Inc.

Provide Current Ratio
for Immunome Inc.

Provide Cash Ratio
for Immunome Inc.

What is the historical Revenue growth
over the last 5 years for Immunome Inc?

What is the historical Net Income growth
over the last 5 years for Immunome Inc?

What is the current Free Cash Flow
of Immunome Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Immunome Inc.

Financials

Balance Sheet Decomposition
Immunome Inc

Current Assets 144.7m
Cash & Short-Term Investments 138.1m
Other Current Assets 6.6m
Non-Current Assets 3.8m
PP&E 3.6m
Other Non-Current Assets 200k
Current Liabilities 21.8m
Accounts Payable 3.3m
Accrued Liabilities 8m
Other Current Liabilities 10.5m
Non-Current Liabilities 6.8m
Other Non-Current Liabilities 6.8m
Efficiency

Earnings Waterfall
Immunome Inc

Revenue
14m USD
Operating Expenses
-42.7m USD
Operating Income
-28.7m USD
Other Expenses
-78.1m USD
Net Income
-106.8m USD

Free Cash Flow Analysis
Immunome Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

IMNM Profitability Score
Profitability Due Diligence

Immunome Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

20/100
Profitability
Score

Immunome Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

IMNM Solvency Score
Solvency Due Diligence

Immunome Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Immunome Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMNM Price Targets Summary
Immunome Inc

Wall Street analysts forecast IMNM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMNM is 36.04 USD with a low forecast of 33.33 USD and a high forecast of 39.9 USD.

Lowest
Price Target
33.33 USD
129% Upside
Average
Price Target
36.04 USD
148% Upside
Highest
Price Target
39.9 USD
174% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

IMNM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

IMNM Price
Immunome Inc

1M 1M
-32%
6M 6M
+67%
1Y 1Y
+181%
3Y 3Y
-42%
5Y 5Y
+21%
10Y 10Y
+21%
Annual Price Range
14.54
52w Low
4.75
52w High
27.34
Price Metrics
Average Annual Return -17.32%
Standard Deviation of Annual Returns 60.11%
Max Drawdown -95%
Shares Statistics
Market Capitalization 868m USD
Shares Outstanding 59 694 200
Percentage of Shares Shorted 6.45%

IMNM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Immunome Inc Logo
Immunome Inc

Country

United States of America

Industry

Biotechnology

Market Cap

868m USD

Dividend Yield

0%

Description

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Exton, Pennsylvania and currently employs 39 full-time employees. The company went IPO on 2020-10-02. The firm's primary focus areas are oncology and infectious diseases. Its discovery platform identifies therapeutic antibodies and their targets by leveraging components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. IMM-ONC-01, is its lead oncology program, which is focused on IL-38. IMM-BCP-01, is its lead infectious disease discovery program with a focus on SARS-CoV-2, the virus that causes COVID-19. The firm is developing an antibody cocktail product candidate by identifying a combination of anti-viral antibodies produced by B cells from COVID-19 super-responders.

Contact

PENNSYLVANIA
Exton
665 Stockton Drive, Suite 300
+16103213700.0
http://immunome.com/

IPO

2020-10-02

Employees

39

Officers

President, CEO & Chairman
Dr. Clay B. Siegall Ph.D.
Interim CFO & Executive VP of Operations
Mr. Max Rosett
Principal Accounting Officer
Mr. Robert Lapetina
Chief Technical Officer
Mr. Philip Roberts
Chief Scientific Officer
Dr. Jack Higgins Ph.D.
Chief Legal Officer, General Counsel & Corporate Secretary
Ms. Sandra G. Stoneman Esq., J.D.
Show More
Chief Strategy Officer
Mr. Bruce Turner M.D., Ph.D.
Chief Medical Officer
Dr. Robert J. Lechleider M.D.
Chief Business Officer
Mr. Kinney Horn
Show Less

See Also

Discover More
What is the Intrinsic Value of one IMNM stock?

The intrinsic value of one IMNM stock under the Base Case scenario is 1.3 USD.

Is IMNM stock undervalued or overvalued?

Compared to the current market price of 14.54 USD, Immunome Inc is Overvalued by 91%.